Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Privium Fund Management B.V.’s 10th Largest Position

Privium Fund Management B.V. boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 258,380 shares of the biopharmaceutical company’s stock after purchasing an additional 15,868 shares during the quarter. Ultragenyx Pharmaceutical makes up 2.5% of Privium Fund Management B.V.’s holdings, making the stock its 10th largest position. Privium Fund Management B.V.’s holdings in Ultragenyx Pharmaceutical were worth $10,870,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Algert Global LLC raised its position in Ultragenyx Pharmaceutical by 46.9% during the third quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock worth $4,105,000 after acquiring an additional 23,580 shares during the period. Bamco Inc. NY purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth about $2,666,000. Principal Financial Group Inc. raised its position in shares of Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after purchasing an additional 76,150 shares during the last quarter. Cerity Partners LLC purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $1,773,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 294 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 73,434 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $3,091,571.40. Following the transaction, the chief executive officer now directly owns 641,731 shares in the company, valued at approximately $27,016,875.10. This represents a 10.27 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the sale, the chief financial officer now owns 106,169 shares of the company’s stock, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,370 shares of company stock worth $5,751,499. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $38.86 on Wednesday. The company’s 50-day moving average is $42.12 and its two-hundred day moving average is $47.74. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The firm has a market capitalization of $3.59 billion, a price-to-earnings ratio of -6.13 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The business had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on RARE. Cantor Fitzgerald reissued an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Wedbush restated a “neutral” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Piper Sandler lowered their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, Wells Fargo & Company boosted their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.71.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.